On the stock market since 1999, it operates in the world of health and science. It has 3,221 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 15% a year over the last 4 years. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 49% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 15% a year on average.
There is $1.6B in the vault; even if every debt were paid off, $917.7M would remain.
Over the last 12 months, company executives reported 34 buys and 17 sells. Management buying with its own money is usually read as a good sign.
The company’s market value is 33 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, BMRN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: BMRN is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.